{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:34:52Z","timestamp":1776479692025,"version":"3.51.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40261-017-0565-5","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T12:50:01Z","timestamp":1504529401000},"page":"1009-1023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety and Efficacy of Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Hussien","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman Ibrahim","family":"Abushouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Menshawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Negida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah A.","family":"Loutfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-2713","authenticated-orcid":false,"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,4]]},"reference":[{"key":"565_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333\u201342. doi:\n                    10.1002\/hep.26141\n                    \n                  .","journal-title":"Hepatology"},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376. doi:\n                    10.1016\/S2468-1253(16)30181-9\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"565_CR3","doi-asserted-by":"publisher","unstructured":"Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513\u201321, 521.e1\u20136. doi:\n                    10.1053\/j.gastro.2009.09.067\n                    \n                  .","DOI":"10.1053\/j.gastro.2009.09.067"},{"key":"565_CR4","doi-asserted-by":"publisher","unstructured":"Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis. 2008;12:661\u201374. doi:\n                    10.1016\/j.cld.2008.03.007\n                    \n                  .","DOI":"10.1016\/j.cld.2008.03.007"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"9270","DOI":"10.3748\/wjg.v20.i28.9270","volume":"20","author":"M-H Lee","year":"2014","unstructured":"Lee M-H, Yang H-I, Yuan Y, et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270\u201380. doi:\n                    10.3748\/wjg.v20.i28.9270\n                    \n                  .","journal-title":"World J Gastroenterol"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/ajg.2015.203","volume":"110","author":"SC Gordon","year":"2015","unstructured":"Gordon SC, Lamerato LE, Holmberg SD, et al. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol. 2015;110:1169\u201377.","journal-title":"Am J Gastroenterol"},{"key":"565_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1213651","author":"TJ Liang","year":"2013","unstructured":"Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013. doi:\n                    10.1056\/NEJMra1213651\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3949\/ccjm.81a.13155","volume":"81","author":"M Dugum","year":"2014","unstructured":"Dugum M, O\u2019Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014;81:159\u201372. doi:\n                    10.3949\/ccjm.81a.13155\n                    \n                  .","journal-title":"Cleve Clin J Med"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MOG.0000000000000062","volume":"30","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol. 2014;30:217\u201322. doi:\n                    10.1097\/MOG.0000000000000062\n                    \n                  .","journal-title":"Curr Opin Gastroenterol"},{"key":"565_CR10","doi-asserted-by":"publisher","unstructured":"Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin. 2015;31(4):290\u20136. doi:\n                    10.1159\/000433594\n                    \n                  .","DOI":"10.1159\/000433594"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973\u201382.","journal-title":"N Engl J Med"},{"key":"565_CR12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594\u2013603. doi:\n                    10.1056\/NEJMoa1315722\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"565_CR13","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983\u201392. doi:\n                    10.1056\/NEJMoa1402338\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"565_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","volume":"64","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I\/II trials. J Hepatol. 2016;64:19\u201328.","journal-title":"J Hepatol"},{"key":"565_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: cochrane book series. Cochrane Handb Syst Rev Interv Cochrane B Ser. 2008. doi:\n                    10.1002\/9780470712184\n                    \n                  .","journal-title":"Cochrane Handb Syst Rev Interv Cochrane B Ser"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1371\/journal.pmed.1000097","volume":"89","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from annals of internal medicine). Phys Ther. 2009;89:873\u201380. doi:\n                    10.1371\/journal.pmed.1000097\n                    \n                  .","journal-title":"Phys Ther"},{"key":"565_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. doi:\n                    10.1136\/bmj.315.7109.629\n                    \n                  .","journal-title":"BMJ"},{"issue":"359\u2013365","key":"565_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(359\u2013365):e1. doi:\n                    10.1053\/j.gastro.2014.04.045\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.27705","volume":"61","author":"K Chayama","year":"2015","unstructured":"Chayama K, Notsumata K, Kurosaki M, et al. Randomized trial of interferon-and ribavirin-free ombitasvir\/paritaprevir\/ritonavir in treatment-experienced hepatitis C virus\u2013infected patients. Hepatology. 2015;61:1523\u201332.","journal-title":"Hepatology"},{"key":"565_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","volume":"64","author":"JJ Feld","year":"2016","unstructured":"Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12\u00a0weeks. J Hepatol. 2016;64:301\u20137.","journal-title":"J Hepatol"},{"key":"565_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346.","journal-title":"Hepatology"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","volume":"63","author":"J Lalezari","year":"2015","unstructured":"Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364\u20139. doi:\n                    10.1016\/j.jhep.2015.03.029\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"971\u2013980","key":"565_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1053\/j.gastro.2015.07.001","volume":"149","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Makara M, Akarca US, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in\u00a0an\u00a0open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015;149(971\u2013980):e1. doi:\n                    10.1053\/j.gastro.2015.07.001\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"565_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jinf.2014.09.008","volume":"70","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Sullivan G, Rodriguez-Torres M, et al. Exploratory trial of ombitasvir and ABT-450\/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70:197\u2013205.","journal-title":"J Infect"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604\u201314.","journal-title":"N Engl J Med"},{"key":"565_CR26","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973\u201382. doi:\n                    10.1056\/NEJMoa1402869\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"565_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.005","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12 weeks. J Hepatol. 2015. doi:\n                    10.1016\/j.jhep.2015.10.005\n                    \n                  .","journal-title":"J Hepatol"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"K KumadaChayama","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L, Suzuki F, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346. doi:\n                    10.1002\/hep.27972\n                    \n                  .","journal-title":"Hepatology"},{"key":"565_CR29","unstructured":"(EMA). EMA Committee for medicinal products for human use (CHMP) assessment report. Exviera. International non-proprietary name: dasabuvir. Procedure No. EMEA\/H\/C\/003837\/0000. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessmen\n                    \n                  ."},{"key":"565_CR30","unstructured":"Perscribing Information: Technivie. 2015.\u00a0\n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207931Orig1s000lbl.pdf\n                    \n                  . Accessed 21 Aug 2017."},{"key":"565_CR31","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3083","author":"H Ahmed","year":"2016","unstructured":"Ahmed H, Elgebaly A, Abushouk AI, et al. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. Antivir Ther. 2016;. doi:\n                    10.3851\/IMP3083\n                    \n                  .","journal-title":"Antivir Ther"},{"key":"565_CR32","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756\u201365.","journal-title":"Lancet"},{"key":"565_CR33","first-page":"716A","volume":"62","author":"P Pockros","year":"2015","unstructured":"Pockros P, Reddy K, Mantry P, et al. RUBY-I: ombitasvir\/paritaprevir\/ritonavir\u00a0+\u00a0dasabuvir\u00a0\u00b1\u00a0ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease. Hepatology. 2015;62:716A.","journal-title":"Hepatology"},{"key":"565_CR34","doi-asserted-by":"publisher","first-page":"568A","DOI":"10.1016\/S0168-8278(15)30865-5","volume":"62","author":"PS Mantry","year":"2015","unstructured":"Mantry PS, Hanson J, Trinh R, et al. Ombitasvir\/paritaprevir\/r and dasabuvir with ribavirin for HCV genotype 1 patients with decompensated cirrhosis. Hepatology. 2015;62:568A\u20139A.","journal-title":"Hepatology"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"1136A","DOI":"10.1002\/hep.27053","volume":"60","author":"DL Wyles","year":"2014","unstructured":"Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV\/HIV-1 coinfected patients treated with ABT-450\/r\/ombitasvir, dasabuvir and ribavirin. Hepatology. 2014;60:1136A\u20137A.","journal-title":"Hepatology"},{"issue":"25","key":"565_CR36","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375\u201382. doi:\n                    10.1056\/NEJMoa1408921\n                    \n                  .\u00a0","journal-title":"N Engl J Med"},{"key":"565_CR37","doi-asserted-by":"publisher","unstructured":"Klibanov OM, Gale SE, Santevecchi B (2015) Ombitasvir\/paritaprevir\/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. doi:\n                    10.1177\/1060028015570729\n                    \n                  .","DOI":"10.1177\/1060028015570729"},{"key":"565_CR38","unstructured":"Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits. 2015;8(Spec Feature):142\u201347."},{"key":"565_CR39","doi-asserted-by":"publisher","unstructured":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932\u201354. doi:\n                    10.1002\/hep.27950\n                    \n                  .","DOI":"10.1002\/hep.27950"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T04:22:13Z","timestamp":1536726133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,4]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0565-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,4]]}}}